Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3beta-Thalassemia 2Lymphoma 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Vasculitis, Central Nervous System 1Thalassemia 1Stiff-Person Syndrome 1Shwachman-Diamond Syndrome 1Sarcoma, Myeloid 1Rhabdomyosarcoma 1Rasmussen subacute encephalitis 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Opsoclonus-Myoclonus Syndrome 1Non-Malignant Neoplasm 1Neuromyelitis Optica 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

ruxolitinib 3venetoclax 2fludarabine phosphate 2duvelisib 2thymoglobulin 1romidepsin 1itacitinib 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Lisaftoclax 1Depsipeptides 1Cyclosporins 1Cyclosporine 1Cladribine 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × thymoglobulin × 1 year × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡